

Yeoungjee Cho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4072763/publications.pdf>

Version: 2024-02-01

136
papers

3,979
citations

147801

31
h-index

149698

56
g-index

137
all docs

137
docs citations

137
times ranked

3627
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 313.	7.4	329
2	Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2021, 372, m4573.	6.0	322
3	ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. <i>Peritoneal Dialysis International</i> , 2022, 42, 110-153.	2.3	209
4	Peritoneal Dialysis-Related Peritonitis: Towards Improving Evidence, Practices, and Outcomes. <i>American Journal of Kidney Diseases</i> , 2014, 64, 278-289.	1.9	178
5	Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. <i>Kidney International</i> , 2010, 77, 904-912.	5.2	154
6	Patient and Caregiver Priorities for Outcomes in Peritoneal Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 74-83.	4.5	101
7	Epidemiology of haemodialysis outcomes. <i>Nature Reviews Nephrology</i> , 2022, 18, 378-395.	9.6	96
8	Multicenter Registry Analysis of Center Characteristics Associated with Technique Failure in Patients on Incident Peritoneal Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1090-1099.	4.5	94
9	Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized) Tj ETQq1 1 0.784314 rgBT /Overlock Diseases, 2020, 75, 404-412.	1.9	92
10	Biocompatible dialysis fluids for peritoneal dialysis. <i>The Cochrane Library</i> , 2014, , CD007554.	2.8	85
11	Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study. <i>American Journal of Kidney Diseases</i> , 2018, 72, 188-197.	1.9	85
12	Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1899-1907.	0.7	75
13	The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. <i>Kidney International</i> , 2013, 84, 969-979.	5.2	73
14	Early and Late Patient Outcomes in Urgent-Start Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2017, 37, 414-419.	2.3	73
15	An international Delphi survey helped develop consensus-based core outcome domains for trials in peritoneal dialysis. <i>Kidney International</i> , 2019, 96, 699-710.	5.2	73
16	Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry. <i>American Journal of Kidney Diseases</i> , 2018, 71, 814-821.	1.9	66
17	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 673-684.	4.5	66
18	Peritoneal Dialysis Use and Practice Patterns: An International Survey Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 315-325.	1.9	62

#	ARTICLE	IF	CITATIONS
19	Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrologyâ€”Children and Adolescents (SONG-KIDS) consensus workshops. <i>Kidney International</i> , 2020, 98, 553-565.	5.2	58
20	Center-Specific Factors Associated with Peritonitis Riskâ€”A Multi-Center Registry Analysis. <i>Peritoneal Dialysis International</i> , 2016, 36, 509-518.	2.3	54
21	Core Outcomes Set for Trials in People With Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2020, 48, 1622-1635.	0.9	47
22	Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients. <i>BMC Nephrology</i> , 2014, 15, 8.	1.8	46
23	Biocompatible dialysis fluids for peritoneal dialysis. <i>The Cochrane Library</i> , 2018, 2018, CD007554.	2.8	46
24	Meaning of empowerment in peritoneal dialysis: focus groups with patients and caregivers. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1949-1958.	0.7	46
25	Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The <i>bal</i> ANZ Trial. <i>Peritoneal Dialysis International</i> , 2017, 37, 283-289.	2.3	40
26	Neutrophilâ€”lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients. <i>Renal Failure</i> , 2016, 38, 70-76.	2.1	39
27	A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study. <i>Blood Purification</i> , 2020, 49, 468-478.	1.8	38
28	Association of micropapillary urothelial carcinoma of the bladder and <scp>BK</scp> viraemia in kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2013, 15, 283-289.	1.7	37
29	Clinical Causes of Inflammation in Peritoneal Dialysis Patients. <i>International Journal of Nephrology</i> , 2014, 2014, 1-9.	1.3	34
30	Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1940-1947.	0.7	34
31	Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2028-2036.	0.7	31
32	Continuous Quality Improvement Initiatives to Sustainably Reduce Peritoneal Dialysis-Related Infections in Australia and New Zealand. <i>Peritoneal Dialysis International</i> , 2016, 36, 472-477.	2.3	28
33	The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study. <i>BMC Nephrology</i> , 2012, 13, 41.	1.8	27
34	Association of Biocompatible Peritoneal Dialysis Solutions with Peritonitis Risk, Treatment, and Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1556-1563.	4.5	26
35	Peritoneal dialysis-associated peritonitis outcomes reported in trials and observational studies: A systematic review. <i>Peritoneal Dialysis International</i> , 2020, 40, 132-140.	2.3	26
36	Clinical Studies of Interventions to Mitigate Cardiovascular Risk in Peritoneal Dialysis Patients. <i>Seminars in Nephrology</i> , 2018, 38, 277-290.	1.6	24

#	ARTICLE	IF	CITATIONS
37	Multicentre registry data analysis comparing outcomes of culture-negative peritonitis and different subtypes of culture-positive peritonitis in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2020, 40, 47-56.	2.3	24
38	Baseline Serum Interleukin-6 Predicts Cardiovascular Events in Incident Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2015, 35, 35-42.	2.3	23
39	Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. <i>American Journal of Kidney Diseases</i> , 2020, 76, 361-373.	1.9	23
40	Perspectives on life participation by young adults with chronic kidney disease: an interview study. <i>BMJ Open</i> , 2020, 10, e037840.	1.9	23
41	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrologyâ€”Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2021, 77, 255-263.	1.9	21
42	Outcomes of integrated home dialysis care: a multi-centre, multi-national registry study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1897-1904.	0.7	20
43	Standardised Outcomes in Nephrologyâ€”Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. <i>Trials</i> , 2017, 18, 560.	1.6	20
44	Early Peritoneal Dialysis Technique Failure: Review. <i>Peritoneal Dialysis International</i> , 2018, 38, 319-327.	2.3	20
45	Identifying patientâ€™important outcomes in polycystic kidney disease: An international nominal group technique study. <i>Nephrology</i> , 2019, 24, 1214-1224.	1.6	20
46	Standardized Outcomes in Nephrologyâ€”Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. <i>Kidney International</i> , 2019, 95, 1280-1283.	5.2	20
47	The Role of Monitoring Vancomycin Levels in Patients with Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2015, 35, 222-228.	2.3	19
48	Urgent-start peritoneal dialysis. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 631-640.	2.0	19
49	Recruitment and retention in clinical trials in chronic kidney disease: report from national workshops with patients, caregivers and health professionals. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 755-764.	0.7	19
50	Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes. <i>International Journal of Nephrology</i> , 2012, 2012, 1-9.	1.3	18
51	Outcomes of <i>Corynebacterium</i> Peritonitis: A Multicenter Registry Analysis. <i>Peritoneal Dialysis International</i> , 2017, 37, 619-626.	2.3	18
52	An Intervention Design: Supporting Skills Development for Peritoneal Dialysis Trainers. <i>Peritoneal Dialysis International</i> , 2019, 39, 134-141.	2.3	18
53	Effects of Climatic Region on Peritonitis Risk, Microbiology, Treatment, and Outcomes: A Multicenter Registry Study. <i>Peritoneal Dialysis International</i> , 2013, 33, 75-85.	2.3	17
54	Weekend Compared with Weekday Presentations of Peritoneal Dialysisâ€”Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2012, 32, 516-524.	2.3	16

#	ARTICLE	IF	CITATIONS
55	Economic Evaluation of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions Compared With Standard Solutions: A Secondary Analysis of the balANZ Trial. <i>American Journal of Kidney Diseases</i> , 2015, 65, 773-779.	1.9	16
56	Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2020, 76, 213-223.	1.9	16
57	Acute hydrothorax complicating peritoneal dialysis: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 355.	0.8	15
58	Peritoneal Dialysis-Related Peritonitis: Atypical and Resistant Organisms. <i>Seminars in Nephrology</i> , 2017, 37, 66-76.	1.6	15
59	Teaching peritoneal dialysis in Australia: An opportunity for improvement. <i>Nephrology</i> , 2018, 23, 259-263.	1.6	15
60	Urgent-start peritoneal dialysis versus haemodialysis for people with chronic kidney disease. <i>The Cochrane Library</i> , 2021, 2021, CD012899.	2.8	15
61	Incremental Versus Standard (Full-Dose) Peritoneal Dialysis. <i>Kidney International Reports</i> , 2022, 7, 165-176.	0.8	15
62	The Role of Monitoring Gentamicin Levels in Patients with Gram-Negative Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2014, 34, 219-226.	2.3	14
63	Association of Socio-Economic Position with Technique Failure and Mortality in Australian Non-Indigenous Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2017, 37, 397-406.	2.3	14
64	The SIESTA Trial: A Randomized Study Investigating the Efficacy, Safety, and Tolerability of Acupressure versus Sham Therapy for Improving Sleep Quality in Patients with End-Stage Kidney Disease on Hemodialysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-10.	1.2	14
65	Patient and caregiver perspectives on burnout in peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2021, 41, 484-493.	2.3	14
66	Effect of patient- and center-level characteristics on uptake of home dialysis in Australia and New Zealand: a multicenter registry analysis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1938-1949.	0.7	14
67	Catheter type, placement and insertion techniques for preventing catheter-related infections in chronic peritoneal dialysis patients. <i>The Cochrane Library</i> , 2019, 2019, CD004680.	2.8	14
68	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. <i>Kidney International</i> , 2021, 100, 1101-1111.	5.2	13
69	Outcomes of <i>Acinetobacter</i> Peritonitis in Peritoneal Dialysis Patients: A Multicenter Registry Analysis. <i>Peritoneal Dialysis International</i> , 2018, 38, 257-265.	2.3	12
70	International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2020, 48, 1612-1621.	0.9	12
71	Standardised Outcomes in Nephrology - Chronic Kidney Disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy. <i>Trials</i> , 2021, 22, 612.	1.6	12
72	Urgent-start peritoneal dialysis versus conventional-start peritoneal dialysis for people with chronic kidney disease. <i>The Cochrane Library</i> , 2020, 12, CD012913.	2.8	12

#	ARTICLE	IF	CITATIONS
73	Perspectives on mental health among patients receiving dialysis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1317-1325.	0.7	12
74	EARLY PERITONITIS AND ITS OUTCOME IN INCIDENT PERITONEAL DIALYSIS PATIENTS. <i>Peritoneal Dialysis International</i> , 2017, , pdi.2017.00029.	2.3	11
75	Patient-led identification and prioritization of exercise interventions for fatigue on dialysis: a workshop report. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 831-839.	2.9	11
76	Time course and dose response of alpha tocopherol on oxidative stress in haemodialysis patients. <i>BMC Nephrology</i> , 2009, 10, 32.	1.8	10
77	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2020, 76, 109-120.	1.9	10
78	Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis. <i>Hemodialysis International</i> , 2021, 25, 322-332.	0.9	10
79	Impact of deceased donor with acute kidney injury on subsequent kidney transplant outcomes—a ANZDATA registry analysis. <i>PLoS ONE</i> , 2021, 16, e0249000.	2.5	10
80	The case for increased peritoneal dialysis utilization in low- and lower-middle-income countries. <i>Nephrology</i> , 2022, 27, 391-403.	1.6	10
81	Does the use of neutral pH, low glucose degradation product peritoneal dialysis fluids lead to better patient outcomes?. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 192-197.	2.0	9
82	The Relationship between Body Mass Index and Organism-Specific Peritonitis. <i>Peritoneal Dialysis International</i> , 2018, 38, 206-214.	2.3	9
83	Targeted Education Approach to improve Peritoneal Dialysis Outcomes (TEACH-PD): A feasibility study. <i>Peritoneal Dialysis International</i> , 2020, 40, 153-163.	2.3	9
84	Outcome measures for technique survival reported in peritoneal dialysis: A systematic review. <i>Peritoneal Dialysis International</i> , 2022, 42, 279-287.	2.3	9
85	Large urate cystolith associated with <i>Proteus</i> urinary tract infection. <i>Kidney International</i> , 2012, 81, 802.	5.2	8
86	Non-Candidal Fungal Peritonitis in Far North Queensland: A Case Series. <i>Peritoneal Dialysis International</i> , 2013, 33, 559-564.	2.3	8
87	Higher Dialysate Matrix Metalloproteinase-2 Levels are Associated with Peritoneal Membrane Dysfunction. <i>Peritoneal Dialysis International</i> , 2016, 36, 16-25.	2.3	8
88	Centre effects and peritoneal dialysis-related peritonitis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 913-915.	0.7	8
89	Evidence for Biocompatible Peritoneal Dialysis Solutions. <i>Contributions To Nephrology</i> , 2017, 189, 91-101.	1.1	8
90	Associations between Peritoneal Glucose Exposure, Glucose Degradation Product Exposure, and Peritoneal Membrane Transport Characteristics in Peritoneal Dialysis Patients: Secondary Analysis of the ANZ Trial. <i>Peritoneal Dialysis International</i> , 2018, 38, 349-355.	2.3	8

#	ARTICLE	IF	CITATIONS
91	Perspectives on blood pressure by patients on haemoand peritoneal dialysis. <i>Nephrology</i> , 2021, 26, 62-69.	1.6	8
92	Rate of decline in residual kidney function pre and post peritoneal dialysis initiation: A post hoc analysis of the IDEAL study. <i>PLoS ONE</i> , 2020, 15, e0242254.	2.5	8
93	Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The BAL Anz Trial. <i>Peritoneal Dialysis International</i> , 2015, 35, 159-171.	2.3	7
94	Long-term outcomes of patients with end-stage kidney disease due to membranous nephropathy: A cohort study using the Australia and New Zealand Dialysis and Transplant Registry. <i>PLoS ONE</i> , 2019, 14, e0221531.	2.5	7
95	GRP78 expression in tumor and perinephric adipose tissue is not an optimal risk stratification marker for clear cell renal cell carcinoma. <i>PLoS ONE</i> , 2019, 14, e0210246.	2.5	7
96	Perspectives on ability to work from patientsâ™ receiving dialysis and caregivers: analysis of data from the global SONG initiative. <i>Journal of Nephrology</i> , 2022, 35, 255-266.	2.0	7
97	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. <i>Kidney International</i> , 2021, 100, 881-893.	5.2	7
98	Establishing a core outcome measure for life participation in patients receiving peritoneal dialysis: A Standardised Outcomes in Nephrologyâ€Peritoneal Dialysis consensus workshop report. <i>Peritoneal Dialysis International</i> , 2022, 42, 562-570.	2.3	7
99	Association between Peritoneal Glucose Exposure and Peritonitis in Peritoneal Dialysis Patients: TheBalANZ Trial. <i>Peritoneal Dialysis International</i> , 2017, 37, 407-413.	2.3	6
100	Multicenter registry analysis comparing survival on home hemodialysis and kidney transplant recipients in Australia and New Zealand. <i>Nephrology Dialysis Transplantation</i> , 2020, 36, 1937-1946.	0.7	6
101	Is Female Sex Really a Risk Factor for Infectious Death in Peritoneal Dialysis?. <i>Peritoneal Dialysis International</i> , 2013, 33, 475-478.	2.3	5
102	Outcomes of Nephrologist-Inserted Peritoneal Catheters in Indigenous Patients from Far North Queensland. <i>Peritoneal Dialysis International</i> , 2014, 34, 663-667.	2.3	5
103	Honey in the Prevention and Treatment of Infection in the CKD Population: A Narrative Review. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-8.	1.2	5
104	â€A sword of Damoclesâ™: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. <i>BMJ Open</i> , 2020, 10, e038005.	1.9	5
105	â€Can I go to Glasgow?â€Learnings from patient involvement at the 17th Congress of the International Society for Peritoneal Dialysis (ISPD). <i>Peritoneal Dialysis International</i> , 2020, 40, 12-25.	2.3	5
106	Kidney Transplant Outcomes in elderly Recipients: An Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry Study. <i>Transplantation Proceedings</i> , 2021, 53, 1915-1926.	0.6	5
107	Practice of Peritoneal Dialysis Catheter Flushing in Australia and New Zealand: Multi-Center Cross-Sectional Survey. <i>Peritoneal Dialysis International</i> , 2018, 38, 98-103.	2.3	4
108	Patient and center characteristics associated with kidney transplant outcomes: a binational registry analysis. <i>Transplant International</i> , 2020, 33, 1667-1680.	1.6	4

#	ARTICLE	IF	CITATIONS
109	Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review. PLoS ONE, 2021, 16, e0252479.	2.5	4
110	Recent Clinical Trials of Pharmacologic Cardiovascular Interventions in Patients with Chronic Kidney Disease: An Update. Reviews on Recent Clinical Trials, 2016, 11, 12-32.	0.8	4
111	Scope and heterogeneity of outcomes reported in randomized trials in patients receiving peritoneal dialysis. CKJ: Clinical Kidney Journal, 2021, 14, 1817-1825.	2.9	4
112	A Core Outcome Set for Trials in Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 53-64.	4.5	4
113	Trials (and Tribulations) of Biocompatible Peritoneal Dialysis Fluids. Peritoneal Dialysis International, 2012, 32, 247-251.	2.3	3
114	Temporal Changes in Deceased Kidney Donor Characteristics in Australia. Transplantation Direct, 2016, 2, e112.	1.6	3
115	Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions. Peritoneal Dialysis International, 2016, 36, 146-153.	2.3	3
116	Early Onset Peritoneal Dialysis-Related Peritonitis. Journal of Clinical & Experimental Nephrology, 2017, 2, .	0.1	3
117	PD Solutions and Peritoneal Health. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1455-1457.	4.5	3
118	Outcome Measures Used to Report Kidney Function in Studies Investigating Surgical Management of Kidney Tumours: A Systematic Review. European Urology Focus, 2019, 5, 1074-1084.	3.1	3
119	Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report. CKJ: Clinical Kidney Journal, 2022, 15, 407-416.	2.9	3
120	DABIGATRAN MAY NOT BE AN EFFECTIVE ANTICOAGULANT FOR HAEMODIALYSIS. Nephrology, 2010, 15, 594-595.	1.6	2
121	Urgent-start peritoneal dialysis versus haemodialysis for people with chronic kidney disease. The Cochrane Library, 0, , .	2.8	2
122	In Reply to "The Importance of Icodextrin Use for Technique and Patient Survival in Peritoneal Dialysis". American Journal of Kidney Diseases, 2018, 72, 309-310.	1.9	2
123	A focus group study of self-management in patients with glomerular disease.. Kidney International Reports, 2021, 7, 56-67.	0.8	2
124	Representativeness of the PDOPPS cohort compared to the Australian PD population. Peritoneal Dialysis International, 2022, 42, 403-414.	2.3	2
125	Associations, microbiology and outcomes of pre-training peritoneal dialysis-related peritonitis. Peritoneal Dialysis International, 2023, 43, 173-181.	2.3	2
126	A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial. Journal of Vascular Access, 2024, 25, 193-202.	0.9	2

#	ARTICLE	IF	CITATIONS
127	Urgent-start peritoneal dialysis versus conventional-start peritoneal dialysis for people with chronic kidney disease. The Cochrane Library, 2018, , .	2.8	1
128	Comparison of graft and patient outcomes following kidney transplantation in extended hour and conventional haemodialysis patients. Nephrology, 2019, 24, 111-120.	1.6	1
129	Raising the standard of trial registration, conduct, and reporting. Peritoneal Dialysis International, 2020, 40, 112-114.	2.3	1
130	Utility of serum beta-trace protein as a tool for estimating residual kidney function in peritoneal dialysis patients. Peritoneal Dialysis International, 2021, 41, 226-235.	2.3	1
131	Establishing a Core Outcome Measure for Peritoneal Dialysis-related Peritonitis: A Standardized Outcomes in Nephrologyâ€™Peritoneal Dialysis Consensus Workshop Report. Kidney International Reports, 2022, , .	0.8	1
132	Centre Effects in Peritoneal Dialysis. , 2018, , .		0
133	FP495PATIENT AND CAREGIVER PRIORITIES FOR OUTCOMES IN PERITONEAL DIALYSIS: AN INTERNATIONAL NOMINAL GROUP STUDY. Nephrology Dialysis Transplantation, 2018, 33, i205-i205.	0.7	0
134	NT-proBNP Concentration and Early Cardiac Dysfunction in Patients Receiving Dialysis: A Prospective Cohort Study. CardioRenal Medicine, 2020, 10, 323-332.	1.9	0
135	Longer antibiotic durations for treating peritoneal dialysis-associated peritonitis: helpful or harmful?. CKJ: Clinical Kidney Journal, 2021, 14, 735-738.	2.9	0
136	Dialysis modality utilization patterns and mortality in older persons initiating dialysis in Australia and New Zealand. Nephrology, 0, , .	1.6	0